Biocon secures Pebrilzo dates as Axis sets INR 424 target for Biocon stock

Published on 10/20/2026 at 01:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pebrilzo targets Europe in 2027 and the US in 2028. Biocon stock posted INR 43.36 billion revenue, up 10.00 percent year over year.

Pebrilzo launch timeline clarified

Biocon secured Pebrilzo launch windows on October 14, 2026, with Europe first in 2027.
Revenue reached INR 43.36 billion in the quarter ended June 30, 2026, up 10.00 percent year over year.
Biocon had a market capitalization of INR 464.5 billion as of October 19, 2026.

Biocon, INE376G01013, Illustration mit AI erstellt.

Biocon secured licensed launch windows for its Pebrilzo biosimilar on October 14, 2026, after settling patent disputes with Genentech. The Economic Times reported that the agreement permits launches in the European Union and United Kingdom in the first quarter of 2027 and in the United States in the third quarter of 2028. Axis Securities had set a INR 424 target on September 19, 2026, according to DSIJ.

Launch timetable reduces legal uncertainty

The settlement gives Biocon a defined commercialization path for Pebrilzo, a proposed pertuzumab biosimilar for HER2-positive breast cancer. Business Standard said the agreement resolves disputes in several jurisdictions, while regulatory approvals remain necessary before commercial sales. The publication also reported that other market launches are permitted between 2026 and 2028.

The commercial opportunity is substantial but not yet quantified. The settlement terms remain confidential, and eventual revenue will depend on approval timing, pricing, competition and market share. The Hindu BusinessLine reported that Biocon's first-quarter fiscal 2027 net profit rose 355.00 percent year over year to INR 1.41 billion, while revenue increased 10.00 percent to INR 43.36 billion.

What does the target mean for margins?

Axis Securities linked its September 19, 2026 target to expanding insulin capacity, biosimilar launches and lower financing costs. Its report said biosimilars generated a 25.00 percent EBITDA margin and that interest expense fell 23.00 percent year over year to INR 2.13 billion. These figures point to operating leverage as the next test for the launch pipeline.

Three dated milestones for Biocon

On August 5, 2026, Biocon reported first-quarter fiscal 2027 revenue of INR 43.36 billion, up 10.00 percent year over year. On September 21, 2026, its pertuzumab biosimilar received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use, as reported by Alpha Inflection. On October 14, 2026, the Genentech settlement established the launch timetable.

Next launch dates

The next material dates are the first quarter of 2027 for the European Union and United Kingdom launch and the third quarter of 2028 for the United States launch. Both remain subject to regulatory approval.

Market value and investor perspective

Biocon was last at INR 340.00 on the NSE on October 19, 2026 at 3:29 p.m. IST. Its market capitalization was INR 464.5 billion, with a 52-week range of INR 337.70 to INR 447.15 on that date. The stock's valuation now depends on whether the clarified launch schedule becomes measurable product revenue.